We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights
GCVRZ

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

Back to rankings

103 hedge funds and large institutions have $140M invested in Sanofi Contingent Value Rights in 2019 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more capital invested

Capital invested by funds: $87.5M → $140M (+$52.1M)

8% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 13

0% more funds holding

Funds holding: 103 → 103 (0)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

27% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 15

Holders
103
Holders Change
–
Holders Change %
0%
% of All Funds
2.03%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
14
Increased
11
Reduced
15
Closed
13
Calls
$17.9M
Puts
–
Net Calls
+$17.9M
Net Calls Change
+$913K

Top Buyers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
+$1.82M
2
Capstone Investment Advisors
Capstone Investment Advisors
New York
+$1.18M
3
OP
Omni Partners
United Kingdom
+$1.11M
4
JCI
Jet Capital Investors
New York
+$729K
5
SCM
Stonehill Capital Management
New York
+$553K

Top Sellers

Rank Fund Capital Flow
1
WC
Wexford Capital
Florida
-$280K
2
NGA
New Generation Advisors
Massachusetts
-$151K
3
BRF
B. Riley Financial
California
-$144K
4
TL
TowerView LLC
New York
-$127K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$100K
Name Holding Trade Value Shares
Change 		Change in
Stake
WEC
51
Winslow Evans & Crocker
Massachusetts
$4K – – –
Royal Bank of Canada
52
Royal Bank of Canada
Ontario, Canada
$4K +$299 +390 +11%
AG
53
Advisor Group
Arizona
$3K +$88 +114 +3%
FHA
54
Flagship Harbor Advisors
Massachusetts
$2K -$9.53K -12,414 -83%
LTFS
55
Ladenburg Thalmann Financial Services
Florida
$2K -$18 -24 -1%
OP
56
Omni Partners
United Kingdom
$1.24K +$1.11M +1,446,247 New
US Bancorp
57
US Bancorp
Minnesota
$1K -$123 -160 -11%
CTC
58
Central Trust Company
Missouri
$1K – – –
EWM
59
Edge Wealth Management
New York
$1K – – –
MCM
60
Manchester Capital Management
Vermont
$1K – – –
RMC
61
Resources Management Corp
Connecticut
$1K – – –
SIM
62
Sonora Investment Management
Arizona
$1K – – –
SCA
63
Stonebridge Capital Advisors
Minnesota
$1K – – –
TFO
64
Tarbox Family Office
California
$1K – – –
WTC
65
WhitTier Trust Company
Nevada
$1K – – –
CBT
66
Capital Bank & Trust
California
$1K +$691 +900 New
AA
67
Ancora Advisors
Ohio
$1K +$921 +1,200 New
RE
68
RBC Europe
United Kingdom
$112 – – –
BCWM
69
Bartlett & Co Wealth Management
Ohio
$86 – – –
KFS
70
Kelly Financial Services
Massachusetts
$65 – – –
CT
71
Caldwell Trust
Florida
$36 +$32 +42 New
ECM
72
Estabrook Capital Management
New York
$12 – – –
SAM
73
Silverback Asset Management
North Carolina
– -$442 -788,011 Closed
WC
74
Wexford Capital
Florida
– -$280K -500,000 Closed
BRF
75
B. Riley Financial
California
– -$144K -256,219 Closed
1 2
3
4

GCVRZ Hedge Fund Activity: Q4 2019 in Review

103 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q4 2019, worth a combined $140M — up 60% from $87.5M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new GCVRZ positions and 13 closed out — a net gain of 1 holder — while 11 added to existing stakes and 15 trimmed.

The largest buyer was Farallon Capital Management, adding an estimated $1.82M. The largest seller was Wexford Capital, exiting entirely with an estimated $280K sold.

  • 103 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q4 2019, unchanged from Q3 2019.
  • Funds reported $140M of Sanofi Contingent Value Rights stock for Q4 2019, up 60% quarter-over-quarter.
  • 14 funds opened new Sanofi Contingent Value Rights positions in Q4 2019 and 13 closed out, a net change of +1 holder.
  • The largest Sanofi Contingent Value Rights buyer in Q4 2019 was Farallon Capital Management, an estimated $1.82M added.
  • The largest Sanofi Contingent Value Rights seller in Q4 2019 was Wexford Capital, an estimated $280K sold.

Based on aggregated 13F filings for Q4 2019.